Loading…
← CockpitCompetitor Analysis › PAHC Phibro Animal Health Corporation Class AOpen in the cockpit ↗

Phibro Animal Health Corporation Class APAHCCompetitor analysis, valuation and peers

United States · USD·Health Care›Pharmaceuticals: Major

Makes animal-health products — medicated feed additives, vaccines and nutritional specialties for livestock and pets.

Momentum neutral 57
Mkt cap
$1.44B
US dollars, full cap
Free float
99%
of shares outstanding
$/day
$7.38M
20-day average traded
Fwd P/E
9.9×
forward earnings
ROIC−WACC
+7.7 pp
WACC 6.6%
Hurdle
-19 pp
Req g minus delivered
Next earnings
84 days
10 Feb 2027
Close · USD$35.57
1D+1.9%
1W+1.2%
1M-8.3%
3M+1.1%
6M+5.2%
YTD-4.8%
1Y-21.1%
ATR %4.3%
Beta0.94
52w lowhigh40.8% off high

What Phibro Animal Health does

Makes animal-health products — medicated feed additives, vaccines and nutritional specialties for livestock and pets.

Sells to producers of chickens, pigs and cattle through feed companies and distributors, with medicated feed additives, which prevent disease in herds, the largest line, and poultry the largest customer group. The Bendheim family keeps control through a separate class of shares.

Products and services

  • Medicated feed additives
  • Vaccines (poultry/livestock)
  • Mineral nutrition/specialty products

Customers

  • Livestock producers
  • Veterinarians
  • Feed companies

Where it sits in the supply chain

  • Animal health
  • Feed additives/vaccines manufacturing
  • Livestock/companion-animal distribution

What could go right

  • Global protein demand growth
  • Vaccine portfolio expansion

What could go wrong

  • Regulatory restrictions on antibiotic use in livestock
  • Commodity/livestock-cycle sensitivity

Moat: narrow (regulatory licence, scale, distribution). Registered animal-drug approvals and an established livestock distribution network limit new entrants.

Headquarters: Teaneck, New Jersey, US · Founded: 1954 · Employees: 2,605

Named competitors

Phibro Animal Health at a glance

Size Phibro Animal Health (PAHC) is a United States Health Care company (Pharmaceuticals: Major) with a market value of $1.44B, the 1994th largest of 3,085 United States companies the cockpit tracks. Shares closed at $35.57 on 18 Nov 2026.

Performance Over six months the shares gained 5.2%, against -14.9% for the median peer and -2.2% for the United States market (cap-weighted) — 4th highest of 21 in its peer set.

Growth Revenue grew 10.1% over the last twelve months (peer median +9.2%); the operating margin is 13.2% (peer median 9.4%).

Valuation It trades at 9.9× forward earnings against a peer median of 23.2× (2nd cheapest of 10).

Price implies For today's price to make sense, revenue must grow about -6% a year for seven years (Req g). Recent delivered growth is +13%, so the hurdle is -19 pp: the price already allows for a slowdown.

Capital Return on invested capital runs 7.7 points above its cost of capital (6.6% WACC).

Short interest Short interest is 4.8% of the free float (30 Oct 2026).

Next results Next results expected around 10 Feb 2027 (exchange calendar; dates can move).

Relative performance

10012021 May 202621 Aug 202618 Nov 2026PAHC 106Peer median 86
Six months, rebased to 100: Phibro Animal Health against the median of its 20 peers (local-currency closes).

Phibro Animal Health financials

Reported figures in USD; fiscal year ends 2026-06-30. TTM = trailing twelve months.
TTMFY2026FY2025FY2024FY2023
Revenue$1.54B$1.52B$1.30B$1.02B$978M
Revenue growth—+17%+27%+4%—
Gross profit$519M$510M$391M$312M$299M
EBITDA$255M$252M$167M$98.6M$114M
Net income$103M$99.7M$48.3M$2.42M$32.6M
Free cash flow$21.7M$9.87M$41.8M$46.4M-$38.5M
Capital expenditure$64.1M$59.1M$38.3M$41.2M$51.8M
Total debt$789M$789M$762M$525M$510M

Quarterly statements and history in the cockpit →

Phibro Animal Health competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-75%-50%-25%0%+25%-20%0%002626140410310210MARKSANS4516DMRACORONA141080002020298380603235600572226950NANO300181SRPT002099068760002019688293PAHC6-month return →1-month return →
Up and to the right = strong over both horizons. Phibro Animal Health is the large dot.

Fundamentals: revenue growth against valuation

0%+50%+100%20×40×60×002626MARKSANS4516CORONA002020600572300181002019688293PAHCRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Phibro Animal Health is the large dot.

Capital: growth delivered against growth the price implies

-20%0%+20%+40%-20%0%20%40%MARKSANS4516CORONA002020603235300181SRPT068760688293PAHCGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Phibro Animal Health is the large dot.

Phibro Animal Health competitors and peer comparison

Head to head with its named competitors (PAHC vs ZTS vs ELAN vs MRK)
CompanyMarket cap6M returnRevenue growthOp. marginForward P/EReq g
Phibro Animal Health PAHC$1.44B+5%+10%13%9.9×-6.4%
Zoetis ZTS$34.8B+7%+1%37%13.8×-2.9%
Elanco Animal Health ELAN$13.3B+28%+12%8%21.5×32.9%
Merck & MRK$340B+23%+5%18%16.4×8.3%

How Phibro Animal Health compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Phibro Animal Health against its 20 peers (data as of 18 Nov 2026)
MeasurePAHCPeer medianRank in peer set
1-month return-8.3%-3.9%8th lowest of 21
6-month return+5.2%-14.9%4th highest of 21
Distance from 52-week high-40.8%-40.7%11th highest of 21
Revenue growth (TTM)+10.1%+9.2%10th highest of 20
Operating margin13.2%9.4%7th highest of 20
Forward P/E9.9×23.2×2nd cheapest of 10
Growth the price implies (Req g, 7 yrs)-6.4%-0.5%4th least demanding of 11
Growth delivered (Del g)+12.7%+16.6%5th lowest of 11
Hurdle (Req g minus delivered)-19.1 pp-7.9 pp3rd least demanding of 11
ROIC minus cost of capital+7.7 pp-1.8 pp4th highest of 20
EV / EBITDA8.4×17.6×2nd cheapest of 5
Net debt / EBITDA2.8×0.1×2nd most indebted of 6

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Phibro Animal Health PAHCUnited States$1.44B+5%+10%13%9.9×-6.4%+12.7%
Xiamen Kingdomway 002626.SZChina$1.45B-3%-3%11%27.2×n/an/a
Mezzion Pharma 140410.KSSouth Korea$1.43B-15%+13%-211%n/an/an/a
Voronoi 310210.KSSouth Korea$1.43B-62%-100%-438,152%n/an/an/a
Marksans Pharma MARKSANS.NSIndia$1.43B+36%+24%20%23.2×31.0%+16.6%
Nippon Shinyaku 4516.TJapan$1.42B-20%+18%18%7.9×-18.1%+7.0%
Damora Therapeutics DMRAUnited States$1.42B-5%n/an/an/an/an/a
Corona Remedies CORONA.NSIndia$1.48B+27%+17%18%58.9×36.3%+16.6%
LigaChem Biosciences 141080.KSSouth Korea$1.48B-72%-55%-324%n/an/an/a
Zhejiang Jingxin Pharmaceutical 002020.SZChina$1.39B-19%+1%19%12.1×-9.6%+4.6%
ABL Bio 298380.KSSouth Korea$1.51B-71%-53%-201%n/an/an/a
JiangXi Tianxin Pharmaceutical 603235.SSChina$1.52B-9%+16%24%n/a-4.9%+0.2%
Zhejiang CONBA Pharmaceutical 600572.SSChina$1.52B-4%+4%9%16.0×-6.1%+1.9%
OliX Pharmaceuticals 226950.KSSouth Korea$1.35B-51%+27%-384%n/an/an/a
Nanobiotix NANO.PAFrance$1.35B-32%-77%-392%n/an/an/a
Zhejiang Jolly Pharmaceutical 300181.SZChina$1.34B-15%+17%20%13.0×3.9%+22.8%
Sarepta Therapeutics SRPTUnited States$1.56B-15%-19%0%n/a-6.8%+32.4%
Zhejiang Hisoar Pharmaceutical 002099.SZChina$1.33B-2%+9%-13%n/an/an/a
Celltrion Pharm 068760.KSSouth Korea$1.33B-23%+16%12%n/a10.2%+18.1%
Yifan Pharmaceutical 002019.SZChina$1.57B-19%-5%8%25.6×n/an/a
Shanghai OPM Biosciences 688293.SSChina$1.32B+36%+133%11%48.6×25.9%+23.1%

Questions

Who are Phibro Animal Health's main competitors?
Named competitors: Zoetis (ZTS), Elanco Animal Health (ELAN), Merck Animal Health (MRK). The cockpit's measured peer set (industry) also includes Xiamen Kingdomway (002626.SZ), Mezzion Pharma (140410.KS), Voronoi (310210.KS), Marksans Pharma (MARKSANS.NS), Nippon Shinyaku (4516.T), Damora Therapeutics (DMRA).
Is Phibro Animal Health expensive compared with its peers?
On forward p/e it trades at 9.9× against a peer median of 23.2×, 2nd cheapest of 10 in its peer set. For today's price to make sense, revenue must grow about -6% a year for seven years (Req g). Recent delivered growth is +13%, so the hurdle is -19 pp: the price already allows for a slowdown.
How has Phibro Animal Health stock performed?
Over six months to 18 Nov 2026 the shares returned +5.2% against -14.9% for the median peer; over one year -21.1%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.